Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Ryan Wilcox
- Target Recruit Count
- 11
- Registration Number
- NCT03547700
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Ajai Chari
- Target Recruit Count
- 5
- Registration Number
- NCT03492138
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 61
- Registration Number
- NCT03439293
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
🇺🇸Research Medical Center - Kansas City, Kansas City, Missouri, United States
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 295
- Registration Number
- NCT03433001
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 45
- Registration Number
- NCT03416374
- Locations
- 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵Kyorin University Hospital, Mitaka, Tokyo, Japan
🇯🇵Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Raija Silvennoinen
- Target Recruit Count
- 120
- Registration Number
- NCT03376672
- Locations
- 🇫🇮
Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital, Oulu, Finland
🇫🇮Päijät-Häme Central Hospital, Lahti, Finland
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT03323151
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Kansas, Overland Park, Kansas, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT03283917
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 28
- Registration Number
- NCT03236792
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-03-20
- Target Recruit Count
- 142
- Registration Number
- NCT03225417
- Locations
- 🇪🇸
Hospital Universitario Vall D´Hebrón, Barcelona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸ICO- Hospital Germans Trias i Pujol, Badalona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.